Table 1:
Patient Characteristics (N=889), late LCNP rate, and mean composite MDADI scores
| Composite MDADI Score ± Standard Deviation) | ||||
|---|---|---|---|---|
| Variables | All Patients (n=889) | Patients with LCNP (n=36) | All patients (n=889) | P-valuea, b |
| Continuous Variables | P-valuea | |||
| Age at diagnosis, median (range) | 56 (32–84) | 57 (42–72) | rho = −0.034 | 0.306 |
| Survival time, median (range) | 7 (1–16) | 10.5 (2–16) | rho = −0.076 | 0.023 |
| Radiation Dose, Gy. median (range) | 70 (40–73) | 70 (60–72) | rho = −0.201 | < 0.001 |
| Categorical Variables | All Patients n (%) | n (%) Patients with LCNP | All patients (n=889) | P-valueb |
| Sex | 0.443 | |||
| Female | 136 (15.3) | 5(3.7) | 78.3 ±17.5 | |
| Male | 753 (84.7) | 31(4.1) | 79.9 ±16.3 | |
| Education | < 0.001 | |||
| ≤Highschool | 168(18.9) | 8(4.8) | 75.6 ±16.7 | |
| >Highschool | 637(71.7) | 27(4.2) | 80.9 ±15.9 | |
| Missing | 84(9.4) | 1(1.2) | 78.6 ±18.9 | |
| Race | 0.983 | |||
| Others | 59(6.6) | 3(5.0) | 78.5 ±20.0 | |
| White | 821(92.4) | 32(3.9) | 79.8 ±16.2 | |
| Missing | 9(1.0) | 1(11.1) | 78.4 ±19.3 | |
| Primary Site | 0.200 | |||
| Tonsil | 438(49.3) | 17(3.8) | 80.3 ±16.4 | |
| Base of Tongue | 451(50.7) | 19(4.2) | 79.1 ±16.6 | |
| T classification | < 0.001 | |||
| 1 | 334(37.6) | 8(2.4) | 82.6 ±15.2 | |
| 2 | 345(38.8) | 13(3.8) | 80.8 ±15.7 | |
| 3 | 131(14.7) | 8(6.1) | 75.8 ±17.0 | |
| 4 | 79(8.9) | 7(8.9) | 68.7 ±18.9 | |
| N classification | 0.007 | |||
| N0 | 81(9.1) | 3(3.7) | 79.9 ±16.1 | |
| N1+2a | 236(26.5) | 7(2.9) | 81.8 ±14.7 | |
| 2b+3 | 429(48.3) | 19(4.4) | 80.1 ±16.4 | |
| 2c | 143(16.1) | 7(4.9) | 74.7 ±18.9 | |
| HPV status | 0.033 | |||
| Negative | 56(6.3) | 2(3.6) | 80.9 ±16.8 | |
| Positive | 429(48.3) | 9(2.1) | 81.0 ±15.9 | |
| Unknown | 404(45.4) | 25(6.2) | 78.1 ±17.0 | |
| Smoking | < 0.001 | |||
| Former | 422(47.5) | 17(4.0) | 79.0 ±16.3 | |
| Current | 58(6.5) | 3(5.2) | 72.5 ±17.9 | |
| Solid Food pre-Tx | 0.846 | |||
| Yes | 879(98.9) | 35(4.0) | 79.9 ±14.0 | |
| No | 10(1.1) | 1(10.0) | 79.7 ±16.5 | |
| Treatment Group | < 0.001 | |||
| Single Modality | 278(31.3) | 11(4.0) | 83.2 ±14.3 | |
| Multimodality | 611(68.7) | 25(4.1) | 78.1 ±17.2 | |
| Treatment Group | 0.001 | |||
| RT alone | 270(30.4) | 11(4.1) | 83.0 ±14.4 | |
| Surgery alone | 8(0.9) | 0 | 89.9 ±9.4 | |
| RT plus systemic | 596(67.0) | 23(3.9) | 78.1 ±17.3 | |
| Surgery plus adjuvant | 15(1.7) | 2(13.3) | 78.4 ±14.2 | |
| Radiotherapy | 0.068 | |||
| No | 8(0.9) | 0 | 89.9 ±9.4 | |
| Yes | 881(99.1) | 36(4.1) | 79.6±16.5 | |
| Chemotherapy | < 0.001 | |||
| No | 284(32.0) | 11(3.9) | 83.0 ±14.3 | |
| Yes | 605(68.0) | 25(4.1) | 78.1 ±17.2 | |
| Surgery | 0.403 | |||
| No | 865(97.3) | 34(3.9) | 79.6 ±16.6 | |
| Yes | 24(2.7) | 2(8.3) | 83.0 ±13.8 | |
| Neck Dissection | 0.431 | |||
| No | 665(74.8) | 27(4.1) | 79.9 ±16.5 | |
| Yes | 224(25.2) | 9(4.0) | 79.0 ±16.5 | |
| RT Schedule | 0.002 | |||
| Standard Fractionation | 778(88.3) | 21(2.7) | 80.3 ±16.1 | |
| Accelerated | 95(10.8) | 15(15.8) | 73.5 ±18.3 | |
| Other | 8(0.9) | 0 | 78.3 ±24.3 | |
| RT Type | < 0.001 | |||
| 3d Conformal | 50(5.7) | 9(18.0) | 67.8 ±20.4 | |
| IMRT-SF | 675(76.6) | 23(3.4) | 79.6 ±16.1 | |
| IMRT-WF | 33(3.8) | 1(3.0) | 74.7 ±17.8 | |
| Proton | 23(2.6) | 1(4.4) | 87.5 ±11.3 | |
| IMRT Ipsilateral | 100(11.3) | 2(2.0) | 84.9 ±14.3 | |
| Dilation/Stricture | < 0.001 | |||
| No | 873 (98.2) | 31(3.6) | 80.0 ± 16.3 | |
| Yes | 16 (1.8) | 5(31.3) | 61.0 ± 14.6 | |
Abbreviations: T, tumor; RT, radiotherapy; MDADI, MD Anderson Dysphagia Inventory (MDADI); rho, Spearman rho; pre-Tx, pre-treatment; 3d Conformal, Three Dimensional (3D) Conformal Radiation Therapy; IMRT-SF, Intensity-modulated radiation therapy with split field technique; IMRT-WF, Intensity-modulated radiation therapy with whole field technique.
a
P-value for Continuous Variables and Composite scores calculated using Spearman Test.
b
P-value for Categorical Variables and Composite scores calculated using Kruskal Wallis Test.